VaxDesign offers an alternative to animal studies

Time magazine profiles the work of VaxDesign, a five-year-old biotech company that has developed simulated human immune systems, mixing blood cells and faux tissue into a special construct that can test a vaccine--"clinical trials in a test tube." Their idea is that a simulated immune system can replace time-consuming animal tests, which have limited value in their ability to indicate an actual human response. Better indications of efficacy at an earlier stage might help prevent large-scale human trials that fail to reach their intended endpoints--as in the recent fiasco involving Merck's AIDS vaccine, which may have heightened volunteers' risk of contracting AIDS. With VaxDesign's MIMIC system, the small immune systems test whether a vaccine will spur the needed antibodies into action.

"The information you get from this type of test is far and beyond what you'd get out of a mouse study," says Michael Rivard, vice president of corporate development at VaxDesign, "both because it's humans and because you can see the effect across a spectrum of genotypes."

- read the article in Time

Related Articles:
UK stops some animal testing. Report
How useful is animal testing for predicting human outcomes? Report

Suggested Articles

Sanofi and GSK have agreed to provide 200 million doses of their vaccine to COVAX, a global effort to develop, produce and equitably distribute doses.

Singapore has suspended the use of two flu vaccines, from SK Bioscience and Sanofi, amid reports of deaths in South Korea after immunization.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.